Compare CNTY & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNTY | GRDX |
|---|---|---|
| Founded | 1992 | N/A |
| Country | United States | United Kingdom |
| Employees | N/A | 2 |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8M | 39.3M |
| IPO Year | 1996 | N/A |
| Metric | CNTY | GRDX |
|---|---|---|
| Price | $1.27 | $4.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 64.5K | ★ 80.8K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.31 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $430,529,000.00 | N/A |
| Revenue This Year | $7.17 | N/A |
| Revenue Next Year | $3.28 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 10.82 | N/A |
| 52 Week Low | $1.23 | $1.87 |
| 52 Week High | $2.85 | $6.93 |
| Indicator | CNTY | GRDX |
|---|---|---|
| Relative Strength Index (RSI) | 40.22 | 43.85 |
| Support Level | $1.24 | $2.16 |
| Resistance Level | $1.47 | $5.30 |
| Average True Range (ATR) | 0.06 | 0.59 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 14.02 | 4.12 |
Century Casinos Inc is a casino entertainment company that develops and operates gaming establishments as well as related lodging, restaurants, horse racing (including off-track betting), and entertainment facilities in North America. The company has five reportable segments based on the geographical locations in which its casinos operate; US East, US Midwest, US West, Canada, and Poland.
GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.